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Summary UsingroutinedatafromHIV-positiveadultpatientseligibleforantiretroviraltherapy(ART),wereporton
routinely collected demographic characteristics and opportunistic diseases associated with pre-ART
attrition (deaths and loss to follow-up). Among 2471 ART eligible patients, enrolled between January
2005 and November 2008, 446(18%) were lost to attrition pre-ART. Adjusted risk factors signiﬁcantly
associatedwithpre-ART attritionincludedage<35 years(OddsRatio,OR 1.4,95%Conﬁdence Interval,
CI 1.1–1.8), severe malnutrition (OR 1.5, 95% CI 1.1–2.0), active pulmonary tuberculosis (OR 1.6, 95%
CI 1.1–2.4), severe bacterial infections including severe bacterial pneumonia (OR 1.9, 95% CI 1.2–2.8)
and prolonged unexplained fever (>1 month), (OR 2.6, 95% CI 1.3–5.2). This study highlights a number
of clinical markers associated with pre-ART attrition that could serve as ‘pointers’ or screening tools to
identify patients who merit fast-tracking onto ART and⁄or closer clinical attention and follow-up.
keywords risk factors, attrition, pre-ART phase
Introduction
Many operational challenges still hinder the goal of
achieving timely universal access to antiretroviral therapy
(ART) in sub-Saharan Africa. One such challenge is high
attrition (deaths and loss to follow-up) among patients
during the pre-ART phase, both those not yet ART eligible
and those eligible and in the preparation phase for ART
(Lawn et al. 2005, 2008; Ingle et al. 2010a; Larson et al.
2010; Zachariah et al. 2010). Finding ways forward to
reduce attrition in these two groups is essential as attrition
here is a proxy indicator of health system and programme
barriers to accessing care. Pre-ART attrition, particularly
among those considered eligible for ART, is particularly
important as this is a highly vulnerable group that is at high
risk of death. These are thus patients who have contact
with the health system but for various reasons do not
manage to pass through the ART ‘gates’ to access life-
saving treatment.
There is a dearth of published information on the
association between opportunistic diseases and pre-ART
attrition among ART eligible patients. Such information
would be useful for identifying speciﬁc patient groups who
should receive priority attention and targeted interventions
to improve their retention in care and expedite ART access.
Using routine data from the Me ´decins Sans Frontie `res
(MSF) supported HIV⁄AIDS programme in Kibera, Kenya,
we report on demographic characteristics and opportunis-
tic diseases associated with attrition among ART eligible
adults before starting ART.
Methods
Study design
This was a retrospective cross-sectional study of routinely
collected programme data.
Study setting and population
The study was conducted in Kibera, an urban slum setting
in Kenya with an estimated population of about 200 000
inhabitants. Migration is common in this slum, and a
considerable proportion of the working population consists
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52of daily migrant workers. Thus, this population is generally
mobile because of the contextual situation.
In Kibera, MSF works in close collaboration with the
Ministry of Health, providing HIV⁄AIDS care and treat-
ment in three comprehensive primary care clinics. This
analysis included all HIV-positive adult patients
(‡15 years) who were ART eligible at the time of
presenting to these clinics between January 2005 and
November 2008.
Referral to the HIV clinic, clinical assessment and ART
eligibility
Patients attend the HIV⁄AIDS and ART clinic either at
their own will after having been diagnosed elsewhere or
because they are formally referred by other health facil-
ities. There are also stand-alone HIV testing sites where
patients undergo HIV testing and are subsequently
encouraged to present to the HIV⁄AIDS clinic for clinical
assessment.
At presentation to the clinics, all patients underwent a
complete assessment during which height and weight were
measured and a full clinical history and examination
conducted to determine WHO HIV diseases staging and
the presence of opportunistic diseases (all clinicians have
been trained in the diagnosis and management of oppor-
tunistic diseases with regular supervision). HIV-positive
adult patients were considered eligible for ART if they were
in WHO clinical stage 3 (either with a CD4 count
<350 cells⁄mm
3 or with unknown CD4 count) or stage 4
(irrespective of CD4 count), or with a CD4 count
<200 cells⁄mm
3 (irrespective of WHO staging) (NASCOP
2005). ART eligible patients received preliminary coun-
selling, returned home and then returned to prepare for
ART initiation, accompanied by a guardian, if possible, to
foster a supportive home environment and reinforce the
importance of treatment adherence. Patients attended
individual counselling sessions to be educated on HIV
infection and the implications of ART. For HIV-TB co-
infected patients, care and treatment for TB is provided in
the same health facility by the same clinician.
There were no active tracing systems in place to trace
patients in the pre-ART phase. The tracing system (like
many others in Africa) only focused on tracing patients
once they had been placed on ART. Thus, existing
mechanisms for tracing only get activated once a patient
has managed to receive ART and not before.
Data collection, patient outcomes and statistical analysis
Information on demographic characteristics and clinical
data (height, weight, WHO stage, and opportunistic
diseases) on initial assessment were obtained from an
HIV⁄AIDS software program (FUCHIA, Epicentre, Paris,
France) into which data is entered daily using standar-
dised data collection sheets in the clinics. Treatment
outcomes were deﬁned and analysed as follows: Attrition
pre-ART included all patients who died or were lost to
follow-up; death was deﬁned as a patient who died
for any reason during the preparatory phase; lost to
follow-up was deﬁned as a patient who never returned to
the ART facility for a period of 1 month or more after
the last scheduled appointment date. There were no
active tracing systems in place to trace patients in the
pre-ART phase. Patients were regarded as being alive
and under follow-up if (i) they were alive and on ART,
and thus by deﬁnition had passed through the pre-ART
phase, or (ii) were still alive and waiting to start
ART. Outcomes for ART eligible patients still waiting to
start ART were censored on 30 November 2008. If the
next date of appointment fell after or within 1 month
before the censor date, these patients were considered
retained in care. Patients who transferred out were those
formally transferred out permanently to another treat-
ment facility.
Risk of attrition was determined by crude odds ratios
(ORs) and adjusted ORs. Adjusted ORs were determined
through multivariate logistic regression. All variables that
were signiﬁcant or of borderline signiﬁcance in the crude
model were included in the multivariate model. Those with
a Walds test P value of <0.15 were kept in the model.
Others were maintained in the model if removing them
resulted in a change of >15% in the odds ratio of variables.
A backward stepwise elimination approach was used until
all remaining variables in the model were signiﬁcant and
this was then reported. All related P-values were based on
the Walds test. Data analysis was performed using the
STATA 8.2 software (Stata corporation, College Station,
Texas 77845, USA).
Ethical approval
Ethical approval was received from the MSF and UNION
Ethics Review Boards (ERB). The MSF ERB is instituted
independently of MSF. The project in Kibera functions
under the framework of formal collaborative agreements
with the Kenyan Ministry of Health. The data in this study
did not include patient identiﬁers, and all data used in this
report constitute what is routinely collected under national
management guidelines for TB and ART. General measures
are provided in the Kibera facilities to ensure patient
conﬁdentiality, consent for HIV testing, and counselling
and support for those who receive a positive HIV test
result.
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Characteristics of the study population
Between January 2005 and November 2008, 2718 ART
eligible adults were registered at the ART sites in Kibera;
247 (9%) had no next appointment date speciﬁed in the
database and were thus excluded from the analysis.
Table 1 shows the case registration characteristics of the
2471 adults included in the study. There were 1532 (62%)
women, and the median age for all patients was 33 years
[Inter-quartile range (IQR), 28–39 years]. The most com-
mon opportunistic infection was Pulmonary TB (PTB)
(11%).
Demographic characteristics and opportunistic diseases
associated with attrition during ART preparation
Out of 2471 ART eligible adults, 446 (18%, 95% CI: 17–
20%) were lost to attrition before starting ART. Loss to
follow-up constituted the largest part of this attrition
(85%). Median time to attrition was 1.1 months (IQR,
0.5–3.1 months, overall range 1 day – 37 months).
Table 2 shows the demographic characteristics and
opportunistic diseases associated with attrition pre-ART.
Age <35 years (OR 1.4, 95%CI 1.1–1.8), severe malnu-
trition (OR 1.5, 95%CI 1.1–2.0), active pulmonary
tuberculosis (OR 1.6, 95%CI 1.1–2.4), severe bacterial
infections (including severe bacterial pneumonia) (OR 1.9,
95%CI 1.2–2.8), and prolonged unexplained fever (for
more than 1 month), (OR 2.6, 95%CI 1.3–5.2) were
signiﬁcantly associated with pre-ART attrition.
Discussion
Younger age (<35 years) and life-threatening opportunistic
diseases were associated with attrition (deaths and loss to
follow-up) among ART eligible patients in pre-ART in an
urban slum setting in Kenya. Although overall attrition
of 18% pre-ART may be deemed acceptable, we believe
that addressing early attrition is important for improving
overall programme outcomes and raising the credibility of
ART programmes.
The strengths of this study are that a large number of
patients were studied, outcomes were available for most
patients and, as the data comes from a programme
setting, ﬁndings likely reﬂect the operational reality on the
ground. The limitations are that the exact cause(s) of
attrition (particularly deaths) could not be determined and
thus attributed cause(s) might be inaccurate, we may have
overestimated attrition as some patients declared lost to
follow-up might include silent undeclared transfers out to
other health facilities, and patients declared lost to follow-
up may include unascertained deaths. In relation to the
latter, as attrition was signiﬁcantly associated with life-
threatening opportunistic diseases, a large undeﬁned
proportion of those declared lost to follow-up might
actually be unascertained deaths, especially as no active
tracing systems were in place to trace these patients
during the pre-ART phase. This belief is also supported by
recent studies from South Africa and Uganda showing
that considerable pre-ART attrition is attributable to
Table 1 Baseline registration characteristics of ART eligible









Median, years (IQR) 33 (28–39)
WHO clinical stage
Stage I or II with CD4 <200 cells⁄ll 551 (22)
Stage III 1439 (58)










Weight loss 99 (4)
Herpes zoster 32 (1)
URTI 80 (3)
Papular pruritic eruption 27 (1)
Unexplained diarrhoea 53 (2)




Pulmonary TB 276 (11)
EPTB 52 (2)
Severe bacterial pneumonia 129 (5)
Severe bacterial infection 50 (2)
Wasting syndrome 23 (1)
Kaposi sarcoma 23 (1)




ART, antiretroviral therapy; IQR, Inter-quartile range; WHO,
World Health Organisation; BMI, Body mass index; URTI, Upper
Respiratory Tract Infection; TB, Tuberculosis, PTB, Pulmonary
TB; EPTB, Extra-pulmonary TB.
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52death (Amuron et al. 2009; Fox et al. 2010; Ingle et al.
2010b).
Attrition tended to occur early on in the pre-ART phase.
Possible reasons for this include the following: delayed
presentation of patients and thus advanced HIV⁄AIDS
disease, delays in ART initiation resulting in long waiting
times and life-threatening HIV-related opportunistic dis-
ease (such as diagnosed or covert PTB) or complications
such as septicaemia and bacteraemia. Programmatically,
this baseline situation is usually ignored because routine
cohort reporting of adverse outcomes (deaths and losses to
follow-up) is traditionally restricted to registered patients
on ART, and thus, the problem of pre-ART attrition
remains unnoticed at programme level (Van Griensven
et al. 2010; Zachariah et al. 2010). As a consequence,
existing patient tracing systems are not deployed for the
beneﬁt of this patient sub-group. As programmes only act
on problems apparent in their reporting, our ﬁndings
suggest that measures need to be implemented to include
all ‘ART eligible patients into routine cohort reporting and
not just those who ‘start ART’.
Being relatively younger was associated with higher
attrition in the pre-ART phase. This may be linked to
younger patients still feeling relatively well at registration
and not perceiving the need to return for treatment. As
most workers in Kibera are casual workers, they might also
have found it difﬁcult to cope with the formalities linked to
ART preparation, while trying to ﬁnd and keep work.
These people may well wait until they become more ill
before seeking ART care. This merits speciﬁc investigation
Table 2 Demographic and clinical charac-
teristics and opportunistic diseases associ-
ated with attrition pre-ART, Kibera, Kenya
Variables Attrition (%) OR Adjusted OR* P-value
Gender
Female 268⁄1532 (17) 1
Male 178⁄939 (19) 1.1 (0.9–1.4)
Age (years)
<35 years 297⁄1488 (20) 1.4 (1.1–1.7) 1.4 (1.1–1.8) 0.01




<17 73⁄321 (23) 1.6 (1.2–2.2) 1.5 (1.1–2.0) 0.02
17–18.4 58⁄315 (18) 1.2 (0.9–1.7) 1.3 (0.9–1.7) 0.34
‡18.5 171⁄1091 (16) 1
Unknown 144⁄744 (19) 1.3 (1.0–1.6)
WHO Stage
Stage 1 & II, CD4 count <200 87⁄551 (16) 1
Stage III (CD4 count <350 or
no available CD4 count)
263⁄1439 (18) 1.2 (0.9–1.6)
Stage IV 96⁄481 (20) 1.3 (1.0–1.8)
Year of enrolment
2005 93⁄499 (19) 1
2006 161⁄704 (23) 1.3 (1.0–1.7)
2007 93⁄690 (14) 0.7 (0.5–9.0)
2008 99⁄578 (17) 0.9 (0.7–1.2)
Weight loss
Absent 427⁄2372 (18) 1
Present 19⁄99 (19) 1.1 (0.6–1.8)
Pulmonary tuberculosis
Absent 383⁄2195 (17) 1 1.6 (1.1–2.4) 0.008
Present 63⁄276 (23) 1.4 (1.0–1.9)
Severe bacterial pneumonia⁄infection
Absent 397⁄2292 (17) 1 1.9 (1.2–2.8) 0.004
Present 49⁄179 (27) 1.8 (1.3–2.5)
Prolonged unexplained fever
Absent 428⁄2420 (18) 1 2.6 (1.3–5.2) 0.008
Present 18⁄51 (35) 2.5 (1.4–4.6)
ART, antiretroviral therapy; OR, odds ratio; WHO, World Health Organisation; BMI,
body mass index.
*Adjusted odds ratios are only presented for variables included in the multivariate model.
￿v
2 test for trend = 7.99, P = 0.005.
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52and probably targeted education and counselling (Brait-
stein et al. 2006).
A particularly interesting ﬁnding was that active PTB,
severe malnutrition, prolonged unexplained fever
(>1 month) and severe bacterial infections were all signif-
icantly associated with pre-ART attrition. Ways forward in
addressing these challenges are thus needed. Attrition was
seen in about one in four PTB patients in the pre-ART
phase. Possible reasons could be (i) time constraints and
difﬁculties related to having to access joint TB treatment
and ART (with each started at different times as recom-
mended), (ii) patients feeling better after starting TB
treatment and deciding to postpone ART initiation, (iii)
shortcomings in TB-HIV collaboration, and (iv) unascer-
tained deaths caused by TB. We believe that the latter may
contribute most to the pre-ART attrition observed as TB is
a leading cause of early deaths among HIV-positive
patients (Lawn et al. 2005, 2008; Etard et al. 2006).
Recent WHO guidelines recommending earlier ART initi-
ation among all HIV-positive TB patients, irrespective of
CD4 count, should simplify the process of ART initiation.
Severe malnutrition, prolonged unexplained fever
(>1 month) and severe bacterial infections were all asso-
ciated with attrition, and like PTB, we believe that
unascertained deaths may contribute to the majority of this
attrition. For instance, severe malnutrition, by further
compromising host immunity, could predispose to life-
threatening superadded infections, increasing the risk of
death. Severe wasting, unexplained fever and severe
bacterial pneumonia (Scott et al. 2000) may be proxy signs
of undiagnosed or ‘occult’ TB, including disseminated TB
(Lucas et al. 1994; Grant et al. 1997; Anglaret et al. 2002).
As such it may be desirable for patients with severe
malnutrition and unexplained fever to undergo more
‘intensiﬁed’ screening for TB, including clinical questioning
about cough for more than 2 weeks, sputum examination
(including, where feasible, sputum cultures), chest X-ray
and abdominal ultrasound for enlarged mesenteric glands.
There is some evidence that the only indication of TB in a
proportion of such patients might be a positive blood
culture but such an investigation remains beyond the reach
of most health facilities in resource-limited settings. This
highlights the need for development and access to better
point-of-care TB diagnostics for such settings. The recently
described Xpert MTB⁄RIF automated molecular test for
Mycobacterium tuberculosis is a step in the right direction
in this regard (Boehme et al. 2010). The importance of
malnutrition and severe blood-stream infections in HIV-I
infected patients in sub-Saharan Africa has been described,
the most frequently incriminated strains being non-typhi
Salmonella, Streptococcus pneumoniae, Escherichia coli
and Shigella sp. (Gilks et al. 1990; Janoof et al. 1992;
Grant et al. 1997; Gilks 1998; Jones et al. 1998; Anglaret
et al. 2002). Blood culture studies in such patients would
be useful to determine the relative contributions of these
pathogens and to determine whether routine, empirical
antibiotic therapy might be justiﬁed.
Finally, the pre-ART attrition observed among ART
eligible patients in Kibera was not as high as has been
reported in other settings such as South Africa and Uganda
(Amuron et al. 2009; Larson et al. 2010). MSF has
supported the MOH-run primary care clinics in Kibera for
some years now and its presence and the additional
ﬁnancial, logistic and human resources that the organisa-
tion brings to its disposal may explain these lower attrition
rates. In other public health facilities that do not have the
additional resources and support from an NGO, one might
expect this pre-ART attrition to be higher.
In conclusion, in an urban slum setting in Nairobi, a
number of clinical markers routinely collected and
recorded during preparation for ART were associated with
a high risk of pre-ART attrition. These variables could
serve as pointers or screening tools to identify patients who
merit fast-tracking onto ART and much closer clinical
attention.
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